Cardioneuroablation in Reflex Syncope (CARDIOSYRE Trial) (CARDIOSYE)

Fundación de investigación HM

Status

Enrolling

Conditions

Reflex Syncope

Treatments

Procedure: cardioneuroablation

Study type

Interventional

Funder types

Other

Identifiers

NCT05513755

Cardioneuroablation in Syncope

Details and patient eligibility

About

Background: Reflex syncope is a disease of benign etiology but in severe cases it can be disabling and it carries a risk of severe trauma. Today, there is no proven etiological treatment and only palliative treatments are used, namely a change in hygienic and dietary habits, certain drugs or, in the most severe cases, the implantation of a pacemaker. Cardioneuroablation is a novel technique that acts by ablating the parasympathetic ganglia located on the external walls of the atria. Several prospective series with promising results have been published, but there are no randomized studies that have validated its efficacy compared to conventional treatment.

Methods: The CARDIOSYRE study is a multicenter, randomized, single-blinded study of patients with reflex syncope. The aim is to recruit, between June 2022 and June 2025, 92 patients with reflex cardioinhibitory syncope in 15 centers and randomize them (1:1 ratio) to two treatment groups: 1) cardioneuroablation intervention; 2) conventional treatment (control group). The primary end-point will be the time to the first syncope and the secondary end-point will be the total incidence of syncope after one year of follow-up. At least 20 recurrences of syncope are expected during a 1-year follow-up. A relative risk of 0.3 and a statistical power of 80% are assumed. The follow-up will be carried out at 3, 6 and 12 months. Cox models will be used to estimate adjusted Hazard ratios.

Enrollment

92 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with reflex syncope (two or more episodes in the last year) and cardioinhibitory response (documentation of asystole >3 seconds coinciding with syncope or >6 seconds outside of syncope or cardioinhibitory response on the tilt test) defined such as heart rate < 40 bpm for at least 10 seconds or asystolic pause > 3 seconds

Exclusion criteria

Patients under 18 years
Any pathology or medical condition that limits survival to less than one year;
Illegal drug use, chronic alcoholism, or total alcohol use >80 g/d
Participation in a clinical trial conducted with drugs or use of a drug in an experimental state during the year prior to inclusion
Patients institutionalized for chronic treatment, with a lack of autonomy and with the impossibility of carrying out clinical follow-ups
Patients with pacemakers, patients with intrinsic disease of the cardiac conduction system or bundle branch block
Patients with structural heart disease.